Objectives: The purpose of the present study is to estimate autoantibody (auto-AB) frequency, clinical characteristics, and 21-day outcome of participants in the Pediatric Acute Liver Failure Study Group (PALFSG) by antinuclear antibody, smooth muscle antibody, and liver-kidney microsomal (LKM) antibody status. Methods: Auto-ABs were determined at local and/or central laboratories. Subjects were assigned to autoimmune hepatitis (AIH), indeterminate, and other diagnoses groups. Results: Between 1999 and 2010, 986 subjects were enrolled in the PALFSG. At least 1 auto-AB result was available for 722 (73.2%). At least 1 auto-AB was positive for 202 (28.0%). Diagnoses for auto-ABþ subjects were AIH (63), indeterminate (75), and other (64). Auto-ABs were more common in Wilson disease (12/32, 37.5%) compared with other known diagnoses (52/253, 20.6%, P ¼ 0.03). LKMþ subjects were younger (median 2.4 vs 9.1 years, P < 0.001) and more likely to undergo liver transplantation (53.3% vs 31.4% P ¼ 0.02) than other auto-ABþ/LKMÀ subjects. Steroid treatment of subjects who were auto-ABþ was not significantly associated with survival and the subgroup with known diagnoses other than AIH had a higher risk of death. Conclusions: Auto-ABs are common in children with acute liver failure, occurring in 28%. Auto-ABþ subjects have similar outcomes to auto-AB negative subjects. LKMþ children are younger and more likely to undergo liver transplantation compared with other auto-ABþ subjects. Although auto-AB may indicate a treatable condition, positivity does not eliminate the need for a complete diagnostic evaluation because auto-ABs are present in other conditions. The significance of auto-AB in pediatric acute liver failure remains uncertain, but LKMþ appears to identify a unique population of children who merit further study.
A cute liver failure (ALF) in children is a rare disease with multiple causes (1) . Autoimmune hepatitis (AIH) is a cause of ALF, yet consensus in establishing diagnostic criteria for this condition in the presence of severe coagulopathy and encephalopathy has not been achieved (2) (3) (4) . A classic combination of elevated IgG, characteristic autoantibodies (auto-AB) (antiÀsmooth muscle antibody [SMA]) or antiÀliver-kidney microsomal antibody [LKM] ), and a liver biopsy showing a plasmacytic infiltrate with either centrilobular or interface hepatitis leading to a consensus diagnosis of AIH and initiation of steroid therapy is infrequent in ALF (2, 5) . In adults with ALF, the presence of
What Is Known
Autoantibodies occur in pediatric acute liver failure. Autoantibodies may indicate autoimmune hepatitis.
What Is New
Autoantibodies detected in 28% of children with acute liver failure and 94% of those with autoimmune hepatitis. Autoantibodies are not significantly associated with 21-day outcomes. Although steroid treatment is not associated with survival in auto-AB positive patients overall, the subgroup of patients with known diagnoses other than AIH had a higher risk of death.
auto-AB appears to be transient in many who have no other features characteristic of AIH (3, 6, 7) . The significance of auto-AB in the setting of ALF is unknown, and auto-AB are often thought to be a nonspecific response to antigens and not involved in the pathogenesis of liver injury (2) .
Auto-AB are present in settings other than AIH. Antinuclear antibody (ANA) is present in 3% to 12% of healthy children, although SMA and LKM are rarely found (8, 9) . Auto-ABs are present in well-characterized chronic liver diseases in children such as chronic viral hepatitis (ANA 8%-23%, SMA 1%-18%, LKM 1%-4%) (10, 11) and primary sclerosing cholangitis (ANA 43%, SMA 28%) (12) and in adults with nonalcoholic fatty liver disease (ANA 21%, SMA 5%) (13) . Auto-AB can also be present in acute or chronic presentations of Wilson disease (14) . These auto-ABs are generally considered to represent epiphenomena and treatment is directed at the primary diagnosis rather than immunosuppression for AIH. It has been assumed that auto-AB in children with ALF may arise similarly from nonspecific liver injury. Some children with ALF and positive auto-ABs have, however, an acute presentation of AIH and respond to steroid therapy. To date, the frequency and significance of auto-AB presence in pediatric acute liver failure (PALF) have not been investigated.
The Pediatric Acute Liver Failure Study Group (PALFSG) is a National Institutes of Health-funded international consortium of pediatric centers that has been collecting data on children with ALF since 1999. Previous data from our group has shown that testing for auto-AB is variable (15) . The goals of the present study are to describe the prevalence, associated clinical features, and outcomes of the finding of positive auto-AB in children in PALF using locally available tests, supplemented by testing using a standardized central laboratory.
METHODS

Pediatric Acute Liver Failure Study Group
Enrollment in the PALF study cohort began in December 1999. The PALF study protocol has been previously described (1) . Institutional review board approval was secured at each of the clinical sites. Briefly, following informed consent, demographic, daily clinical, and laboratory information was recorded on case report forms for up to 7 days after enrollment and outcome was assessed up to 21 days or until death, liver transplantation, or hospital discharge without liver transplantation (survival with native liver) if occurring 21 days or less after enrollment (1) . Diagnostic evaluation and medical management strategies were consistent with the standard of care at each site and were not determined by the PALF protocol. Completed data forms were forwarded to the Data Coordinating Center. Patients from birth through 17 years of age were eligible for enrollment, if they met the following criteria: no known evidence of chronic liver disease, biochemical evidence of acute liver injury, and hepatic-based coagulopathy defined as prothrombin time (PT) !15 seconds or international normalized ratio !1.5 not corrected by vitamin K in the presence of hepatic encephalopathy or PT !20 seconds or international normalized ratio !2.0 regardless of the presence or absence of clinical hepatic encephalopathy. After enrollment, a single serum sample was to be collected daily for up to 7 days, or until death, liver transplantation, or discharge from hospital. The serum sample was divided into aliquots, frozen at À808C at the enrollment site and batch-shipped to the National Institute of Diabetes and Digestive and Kidney Disease biorepository for long-term storage. The frequency and volume of serum that could be collected for research purposes was dependent upon participant weight, hemoglobin, and the daily volume of blood required for diagnosis and patient management. Given these safety restrictions, research samples were not available at all potential time points for all participants. The underlying etiology of liver dysfunction, based on standard laboratory tests obtained clinically at each center and investigator judgment, included indeterminate, acetaminophen (APAP) toxicity, AIH, infectious, non-APAP drug-induced liver disease, metabolic liver disease, shock, and other (eg, Budd-Chiari syndrome, hemophagocytic syndrome, leukemia, gestational alloimmune liver disease, and veno-occlusive disease) based on agreed upon criteria in the PALF study.
Autoantibody Determination
Auto-AB was measured at the discretion of individual centers at their laboratory of choice. For these analyses, laboratoryspecific cutoffs were used to consider a value positive. In addition, supplemental funding was used to obtain more complete data for PALF participants enrolled between January 1, 2000 and November 23, 2007. This testing was not available for other participants. Samples were batch shipped to a central laboratory to perform the assays. All 3 markers were to be measured on all participants with available samples. If the sample, however, had insufficient volume to measure all markers, ANA was the highest priority, followed by SMA then LKM. Central autoimmune marker testing occurred for PALF participants with a sufficient sample, regardless of autoimmune marker results from local laboratories. The central laboratory used an enzyme-linked immunosorbent assay to measure LKM (Inova Diagnostics, San Diego, CA, Revision 1, March 2000) and ANA (Bio-Rad Laboratories, Hercules, CA), whereas SMA was measured using indirect immunofluorescence. Titers were not available for many of the subjects; thus, auto-ABs were recorded as either positive or negative based on local or central laboratory cutoffs. For this report, if any of the tested auto-ABs was positive, the participant was considered to be auto-ABþ. If all of the tested auto-ABs (which ranged from 1 to 3 for each participant) were negative, the participant was considered to be auto-ABÀ. Each auto-ABþ and auto-ABÀ subject was classified into 1 of 3 diagnostic groups: auto-ABþ AIH (based on the investigator final diagnosis, which did not use the international AIH score because it was not validated for PALF and there were limited data on IgG levels), auto-ABþ or auto-ABÀ with no identified diagnosis (indeterminate) or auto-ABþ or auto-ABÀ with a specific diagnosis other than AIH (Other). If there were discrepant results between the local laboratory and the central laboratory, the auto-AB was considered to be positive if any result was positive. We defined steroid treatment as prednisolone or prednisone therapy and excluded hydrocortisone for stress dosing. Before 2006, steroid treatment was not collected in the present study.
Statistics
Pearson chi-square tests or exact chi-square tests were used to test for differences in the proportions of participants in each category of demographics, encephalopathy, steroid use, and outcome among 3 final diagnosis groups and among the groups with different types of auto-ABþ. The Wilcoxon rank-sum test or Kruskal-Wallis test was used to test for differences in the distributions of continuous age and laboratory values by the final diagnosis groups and among the groups with different types of auto-ABþ. These same statistical tests were used when subsets were tested. A multinomial logistic regression model was used to estimate the association of type of auto-ABþ and of final diagnosis with outcome, adjusting for age. The P values for post-hoc analysis of differences between final diagnosis groups for each variable were adjusted using the Holm-Bonferroni method (16) . P < 0.05 determined statistical significance. All authors had access to the study data and reviewed and approved the final manuscript. Auto-ABþ children were older, slightly more likely to be female (P ¼ 0.047) and Hispanic (P ¼ 0.01) compared to those who were tested and auto-AB negative (Table 1) . Children who were auto-ABþ with indeterminate ALF were younger than children with auto-ABþ AIH (P ¼ 0.03) or other diagnoses (P ¼ 0.03, Table 1 ). Children with auto-ABþ AIH underwent liver biopsy more frequently than children with either indeterminate (P ¼ 0.02) or other diagnoses (P < 0.0001) with positive auto-AB ( Table 1 ).
RESULTS
Of
The auto-AB patterns by group are shown in Table 2 . The patterns varied among the three diagnostic groups. Subjects with AIH were more likely to have at least 2 positive auto-AB with 31.8% with 2 auto-AB for AIH compared with 14.7% for indeterminate (P ¼ 0.03) and 12.5% for other diagnoses (P ¼ 0.03).
We investigated auto-AB concordance between the central laboratory and the local laboratories. Of the 722 subjects, 410 had auto-AB results available only from local testing, 100 subjects had results available only from testing at the central laboratory, and 212 subjects had results available from both local and central laboratory testing. From subjects with testing at both local and central laboratories, 53 were auto-ABþ by local testing, with only 20 (37.7%) of these 53 subjects auto-ABþ by central testing. Conversely, 159 were auto-ABÀ by local testing and 139 (87.4%) of these were auto-ABÀ by central testing, leaving 20 subjects who were auto-AB-by local testing who were auto-ABþ by central testing.
Clinical and laboratory features are shown in Table 3 . Compared with auto-ABþ participants with indeterminate or other specified diagnosis, a larger percentage of subjects with AIH tended to have no or mild encephalopathy (P ¼ 0.003 compared with indeterminate and 0.007 to other diagnoses) and higher likelihood of treatment with steroids (P < 0.0001 compared with indeterminate or other diagnoses). A higher percentage of auto-ABþ participants with indeterminate diagnosis had intensive care unit stays in the first 7 days after enrollment than auto-ABþ participants with AIH (P < 0.001) or other specified diagnosis (P ¼ 0.04). Copyright © ESPGHAN and NASPGHAN. All rights reserved.
Among auto-ABþ participants diagnosed with AIH, a greater percentage of participants survived with native liver for at least 21 days (73.0%) and smaller percentage died (1.6%) or underwent liver transplantation (25.4%) compared with those who were auto-ABþ with an indeterminate (42.7%, 9.3%, 48.0%, P ¼ 0.002) diagnosis (all outcomes across all diagnostic groups P ¼ 0.002, Table 3 ). There was not a significant difference in outcome by auto-AB status in those with indeterminate or other diagnosis (Table 3) .
LKM positivity is associated with type 2 AIH and we sought to determine whether there were differences in those participants who were LKMþ (with or without ANA and/or SMA positivity). LKMþ did not differ significantly with respect to sex, race, alanine aminotransferase (ALT), or PT at presentation compared with auto-ABþ/non-LKMþ participants (Table 4) . LKMþ subjects had a similar rate of undergoing a liver biopsy before liver transplant (8/ 16, 50%) compared to SMAþ and/or ANAþ without LKMþ (32/ 54 59%) subjects. The subjects with LKMþ tended to be younger (P < 0.0001). Liver transplantation was less likely in the subjects with SMAþ and/or ANAþ without LKMþ than the subjects with LKMþ (age-adjusted odds ratio ¼ 0.39, P ¼ 0.03). Table 5 shows 21-day outcome of the first event to occur, among death, liver transplantation, and survival with native liver, between auto-ABþ participants who were treated with steroids and those who were not. Steroid treatment data were only available for 94 (47%) of the auto-ABþ subjects. Data regarding dose were even more limited, so it was not examined. Steroid treatment was not significantly associated with outcome in auto-ABþ subjects with steroid treatment data recorded (P ¼ 0.19) with 57% survival with Percentage is for number who received therapeutic steroids (prednisone or prednisolone) out of total with available data. native liver in steroid-treated compared with 53% in untreated. For the 33 (of 63, 52%) with AIH and the 29 (of 75, 39%) with indeterminate and reliable steroid data, outcomes were not significantly different between those with or without steroid treatment, but with only 4 of 33 not treated, the ability to detect even moderate differences is low. In the 32 of 64 (50%) with other established diagnoses and steroid data, 21-day outcomes were distributed differently between the participants who received steroids and those who did not, with more deaths and less spontaneous survival in those receiving steroids (P ¼ 0.046). Twenty-one-day outcomes did not differ significantly (P ¼ 0.13) by auto-AB type (Table 6 ), but only 2 of 10 (20%) of LKMþ participants who received steroids versus 4 of 5 (80%) who did not receive steroids underwent transplantation.
DISCUSSION
This is the first pediatric study to report the frequency of auto-AB in a large cohort of children with ALF. Our aims were to describe features of auto-ABþ and auto-AB-cohorts and reveal challenges of interpreting results of auto-AB testing when performed by a local or central laboratory. Although it is commonly assumed that auto-ABs can occur in the setting of acute liver failure, we found only 28% of PALF participants had at least 1 auto-AB present among those who had testing performed either by local or central laboratory. This is lower than the 62% frequency of auto-AB among adults with indeterminate ALF (3), but similar to the 32% frequency of auto-AB reported in another study of adults with ALF (6). As expected, auto-ABs were more common in the children with a final diagnosis of AIH (93%) than children with other causes of ALF. More of the children with AIH (64%) underwent a liver biopsy as part of their evaluation than did those with an indeterminate diagnosis (43%). We do not have data to explain this discrepancy. Liver biopsy histology may lead to the consideration of AIH; however, the role of liver biopsy in children with ALF who are also auto-ABþ is not clear from our data. Diagnostic criteria for adults with AIH presenting with ALF or acute severe hepatitis are evolving (2-4), but similar criteria have not been validated in children. Among participants with auto-AB testing at local and central laboratories, we found the concordance of autoAB-results between the 2 testing facilities to be weak. Many factors likely contribute to this, including samples taken at different times, disease progression, and assay differences. Although the interlaboratory variation in auto-AB methods and reporting is a weakness in the present study, our goal in the present study was not to compare auto-AB assays, so we included any evidence of auto-ABþ in the definition. Therefore, in the absence of a ''criterion standard'' methodology being available at all sites, interpretation of auto-AB results remains with the clinician at the bedside.
An important question is whether the presence of one or more auto-AB is associated with outcomes. In that regard, we found that having auto-ABs was not associated with a different 21-day outcome compared to subjects without auto-AB. PALF auto-ABþ subjects with AIH, however, had a greater likelihood of surviving with their native liver than non-AIH auto-ABþ patients (73% vs 51%, P ¼ 0.004). Also, those auto-ABþ with AIH had a greater spontaneous survival rate than auto-ABÀ subjects with indeterminate or other diagnoses (73% vs 54%, P ¼ 0.005). This may be related to differences in medical management or to a less aggressive course for AIH-associated PALF. Steroid treatment is generally the initial treatment for AIH. Because of the study design, steroid treatment data were limited to the first 7 days of the study and was only available on 94 auto-ABþ subjects. For the 33 subjects diagnosed with AIH for whom steroid treatment information was available, 88% received steroids in the first week, whereas only 34% of indeterminate auto-ABþ and 25% of other diagnoses who were auto-ABþ received steroids in the first week after enrollment.
Although there was not a significant difference in outcome between those auto-ABþ subjects who received steroid treatment during the first 7 days and those who did not, steroid treatment information was only available for 47% of those who were auto-ABþ, which may preclude an accurate assessment of the effect of steroids in auto-ABþ PALF. The LKMþ subjects with PALF were younger and more likely to be diagnosed with AIH (57%) compared with SMAþ or ANAþ without LKMþ (27%) subjects. Although the data are limited by small numbers, it is interesting that none of the 15 LKMþ participants whose steroid treatment status was known died, regardless of whether they had steroid treatment (n ¼ 10) or not (n ¼ 5). Four out of the 5 who did not have steroid treatment and only 2 of 10 who received steroids underwent transplantation. We suggest that the issue of steroid treatment in LKMþ subjects with PALF deserves further study in a larger cohort.
Overall, steroid treatment was not significantly associated with improved 21-day survival with native liver in the auto-ABþ group as a whole compared with those who did not receive steroids. Of concern, there was a trend toward more deaths in auto-ABþ subjects with other diagnoses who received steroids compared with those who did not, suggesting that in some causes of PALF, steroids may be detrimental or that steroids are more commonly used in children with more severe illness outside of AIH. In the adult ALF study the association of steroid treatment on spontaneous survival in AIH, indeterminate and drug-induced ALF was investigated, independent of auto-AB status. Steroid treatment also did not improve spontaneous or overall survival with a trend toward increased mortality in the patients with high MELD who received steroids (17) . Although steroid treatment did not affect 21-day outcomes, it is important to note that outcomes after 21 days were not assessed in the present study. At this point, steroid use cannot be routinely recommended outside of treatment for AIH-associated ALF in children, except in the context of a clinical trial that evaluates both short-and longer-term outcomes.
The present study is the largest series to investigate auto-AB in children with ALF. Most of the auto-AB determinations were performed at local laboratories. Thus there are likely a variety of methods and cutoffs for positive values that were used. In addition, there was variability in the timing of the auto-AB determination.
Despite these issues, we have shown that auto-ABs are common in children with ALF. Only 1 of 30 (3.3%) children who were LKMþ regardless of ANA or SMA status died, whereas 14 of 172 (8.1%) of those who were either ANAþ or SMAþ, but LKMÀ or LKM unknown died. We propose that the role of auto-AB in the pathophysiology of ALF in children and their association with specific outcomes should be the subject of further investigation.
